FDG-PET can help diagnose Alzheimer’s disease sooner than usual and lead to better patient outcomes through the use of disease-specific medication.  The finding comes from researchers at the University of California, Los Angeles (UCLA), who presented the study on September 26 at the Medicinal Biotech Forum in China.  A team led by principal investigator Dr. Daniel Silverman, PhD, professor of molecular and medical pharmacology, examined 63 patients who underwent FDG-PET and neuropsychological testing at baseline. {read more here}